Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Melanoma (Skin) Clinical Trial

Official title:

Pilot Study of Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03543969
• Other study ID #: MCC-19441
• Status: Recruiting
• Phase: Early Phase 1
• Start date: June 14, 2018
• Est. completion date: July 2028

Study information

• Verified date: June 2024
• Source: H. Lee Moffitt Cancer Center and Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot early phase I trial studies how well encorafenib, binimetinib, and nivolumab work in treating patients with BRAF mutant stage IIIC-IV melanoma. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with nivolumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving encorafenib, binimetinib, and nivolumab may kill more tumor cells.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 13
• Est. completion date: July 2028
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must be 18 years of age or above

• Subjects must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V600E mutation determined by pyrosequencing assay or equivalent genotyping assay in a Clinical Laboratory Improvement Act (CLIA) certified laboratory, meeting one of the following American Joint Committee on Cancer (AJCC) (8th edition) staging criteria:

• AJCC stage IV

• AJCC stage IIIC or IIID with unresectable nodal/locoregional involvement

• Subjects must have baseline plasma ctDNA >= 0.5 copy/ul at time of study enrollment

• Hemoglobin >= 8.0 g/dL

• Absolute neutrophil count >= 1,500/mcL

• Platelets >= 75,000/mcL

• Total bilirubin =< 2 institutional upper limit of normal (ULN), unless suspected Gilbert's syndrome

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN (in participants with liver metastases =< 5 x ULN)

• Creatinine =< 2.0 institutional ULN

• Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2

• Negative serum pregnancy test within 7 days prior to commencement of dosing in premenopausal women. Women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for >= 1 year

• Fertile men and women must use an effective method of contraception during treatment and for at least 6 months after completion of treatment as directed by their physician. (NOTE: Patients must agree to not use hormonal contraceptives, as encorafenib can result in decreased concentration and loss of efficacy.)

• Patients on non-biologic disease modifying agents (e.g. methotrexate) or patients on corticosteroids =< 10 mg prednisone daily or equivalent are permitted to enroll

• Patients must not have had grade 3 or 4 immune-related adverse events on nivolumab that required more than 12 weeks of immune suppression with corticosteroids

• No anti-PD-1/PD-L1 or BRAF/MEK inhibitor therapy in the metastatic setting is allowed; these treatments are allowed if given in neoaduvant or adjuvant setting > 24 weeks ago. Prior radiation therapy is permitted. All adverse events associated with prior systemic therapy or radiation therapy must have resolved to =< grade 1 prior to start of study

• Subjects must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

Exclusion Criteria:

• Female subjects who are pregnant, intend to become pregnant or are nursing

• Patients previously treated with BRAF/MEK inhibitor or anti-PD-1/PD-L1 therapy in the metastatic setting

• Uncontrolled intercurrent illness including, but not limited to, serious infection. Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better

• Patients with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test and within 90 days prior to randomization

• Patients with untreated or uncontrolled brain metastases. Patients with asymptomatic brain metastases which have been previously treated (with locoregional treatment such as radiation or surgery) and are clinically stable (i.e. not requiring corticosteroids) at the time of study start will be eligible

• Previous malignancy is not an exclusion provided that the other malignancy is considered under control, patient is not on concomitant anti-cancer drug therapy, and target lesions from melanoma are clearly defined for response assessment

Related Conditions & MeSH terms

• Melanoma
• Melanoma (Skin)
• Skin Cancer
• Skin Carcinoma
• Skin Melanoma

Intervention

Drug:
• Encorafenib
450 mg encorafenib daily by mouth
• Binimetinib
45 mg binimetinib daily by mouth
• Nivolumab
240 mg Nivolumab IV every 2 weeks

Locations

Country	Name	City	State
United States	H. Lee Moffitt Cancer Center and Research Institute	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
H. Lee Moffitt Cancer Center and Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	8 Week Completion Rate	Number of participants who reach 8 weeks with the prescribed on/off schedule without progression of disease. Progression as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.	At the end of the first 8 week treatment period
Secondary	Time to Treatment Failure	Time to treatment failure, defined as the time from the day of first dose of study drugs to the first day of treatment with another regimen or with the same regimen in a non-adaptive fashion.	Up to 5 years
Secondary	Objective Tumor Response Rate	Number of participants with tumor response. Response according to RECIST 1.1.	Up to 5 years

External Links

•   Moffitt Cancer Center Clinical Trials website